ABBV vs. AZN, NVS, ABT, LLY, JNJ, MRK, PFE, BMY, ZTS, and RPRX
Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceutical preparations" industry.
AstraZeneca (NASDAQ:AZN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
AstraZeneca has higher earnings, but lower revenue than AbbVie. AstraZeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
AstraZeneca has a net margin of 13.30% compared to AstraZeneca's net margin of 11.02%. AstraZeneca's return on equity of 179.47% beat AbbVie's return on equity.
AstraZeneca has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.4%. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 184.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie has increased its dividend for 52 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
AstraZeneca presently has a consensus target price of $88.00, suggesting a potential upside of 12.07%. AbbVie has a consensus target price of $186.31, suggesting a potential upside of 2.27%. Given AbbVie's stronger consensus rating and higher possible upside, research analysts clearly believe AstraZeneca is more favorable than AbbVie.
AbbVie received 1255 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 73.27% of users gave AbbVie an outperform vote while only 59.79% of users gave AstraZeneca an outperform vote.
In the previous week, AbbVie had 35 more articles in the media than AstraZeneca. MarketBeat recorded 65 mentions for AbbVie and 30 mentions for AstraZeneca. AbbVie's average media sentiment score of 0.82 beat AstraZeneca's score of 0.47 indicating that AstraZeneca is being referred to more favorably in the media.
Summary
AbbVie beats AstraZeneca on 15 of the 22 factors compared between the two stocks.
Get AbbVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
